TABLE 2.
FDA-approved immunotherapeutics since the beginning of 2018
| Drugs | Mechanism of Action | Targeted Disease | Release Date |
|---|---|---|---|
| Durvalumab (IMFINZI, AstraZeneca) | Checkpoint immunotherapy targeting PD-1/PD-L1 pathway | Stage III non–small-cell lung cancer | February 16, 2018 |
| Brentuximab vedotin (Adcetris, Seattle Genetics, Inc.) | Antibody-drug conjugate targeting the CD30 receptor | Untreated classic Hodgkin lymphoma | March 20, 2018 |
| Blinatumomab (Blincyto, Amgen Inc.) | Bispecific T cell–engaging antibody targeting CD19 receptor | B-cell precursor acute lymphoblastic leukemia | March 29, 2018 |
| Nivolumab (Opdivo, Bristol-Myers Squibb) + ipilimumab (Yervoy, Bristol-Myers Squibb) | Checkpoint immunotherapy targeting PD-1 and CTLA-4 | Advanced renal cell carcinoma | April 16, 2018 |
| Tisagenlecleucel (Kymriah, Novartis) | CAR-T cell immunotherapy targeting CD19 receptor | Relapsed/refractory large B-cell lymphoma | May 01, 2018 |
| Pembrolizumab (Keytruda, Merck) | Checkpoint immunotherapy targeting PD-1 | Cervical cancer | June 12, 2018 |
| Pembrolizumab (Keytruda, Merck) | Checkpoint immunotherapy targeting anti–PD-1 | Adult and pediatric primary mediastinal large B-cell lymphoma | June 13, 2018 |
| Nivolumab (Opdivo,l Bristol-Myers Squibb) + ipilimumab (Yervoy, Bristol-Myers Squibb) | Checkpoint immunotherapy targeting PD-1 and CTLA-4 | Relapsed colorectal cancer with high microsatellite instability or deficient DNA mismatch repair | July 10, 2018 |
| Nivolumab (Opdivo, Bristol-Myers Squibb) | Checkpoint immunotherapy targeting PD-1 | Metastatic small-cell lung cancer | August 17, 2018 |
PD-1, programmed death-ligand 1.